The cytoplasmic spleen tyrosine kinase (SYK) is a key regulator of signal transduction events, apoptosis and orderly cell cycle progression in B-lineage lymphoid cells. Although SYK has not been linked to a human disease, defective expression of the closely related T-cell tyrosine kinase ZAP-70 has been associated with severe combined immunode®ciency. Childhood CD19 +
The cytoplasmic spleen tyrosine kinase (SYK) is a key regulator of signal transduction events, apoptosis and orderly cell cycle progression in B-lineage lymphoid cells. Although SYK has not been linked to a human disease, defective expression of the closely related T-cell tyrosine kinase ZAP-70 has been associated with severe combined immunode®ciency. Childhood CD19 + CD10
7 pro-B cell acute lymphoblastic leukemia (ALL) is thought to originate from B-cell precursors with a maturational arrest at the pro-B cell stage and it is associated with poor prognosis. Since lethally irradiated mice reconstituted with SYK-de®cient fetal liver-derived lymphohematopoietic progenitor cells show a block in B-cell ontogeny at the pro-B to pre-B cell transition, we examined the SYK expression pro®les of primary leukemic cells from children with pro-B cell ALL. Here we report that leukemic cells from pediatric CD19 + CD10 7 pro-B cell ALL patients (but not leukemic cells from patients with CD19 +
CD10
+ common pre-pre-B cell ALL) have markedly reduced SYK activity. Sequencing of the reverse transcriptase-polymerase chain reaction (RT ± PCR) products of the Syk mRNA in these pro-B leukemia cells revealed profoundly aberrant coding sequences with deletions or insertions. These mRNA species encode abnormal SYK proteins with a missing or truncated catalytic kinase domain. In contrast to pro-B leukemia cells, pre-pre-B leukemia cells from children with CD19 + CD10
+ common Blineage ALL and EBV-transformed B-cell lines from healthy volunteers expressed wild-type Syk coding sequences. Examination of the genomic structure of the Syk gene by inter-exonic PCR and genomic cloning demonstrated that the deletions and insertions in the abnormal mRNA species of pro-B leukemia cells are caused by aberrant splicing resulting in either missplicing, exon skipping or inclusion of alternative exons, consistent with an abnormal posttranscriptional regulation of alternative splicing of Syk pre-mRNA. Our ®ndings link for the ®rst time speci®c molecular defects involving the Syk gene to an immunophenotypically Introduction SYK is a physiologically crucial 72 kDa pan-B cell tyrosine kinase which is abundantly expressed in the cytoplasm of B-lineage lymphoid cells from the pro-B cell stage to plasma cell stage throughout the B-cell ontogeny (Law et al., 1994) . SYK has been shown to serve as a key regulator of multiple biochemical signal transduction events and biologic responses in B-lineage lymphoid cells. (Bolen, 1995; Bolen and Brugge 1997; Chan and Shaw, 1996; Deckert et al., 1996; Gulbins et al., 1994; Harmer and DeFranco, 1997; Kurosaki et al., 1995; Latour et al., 1996 Latour et al., , 1998 Law et al., 1996; Li et al., 1997; Nagai et al., 1995; Panchamoorthy et al., 1996; Qin et al., 1998; Sidorenko et al., 1995; Sieh et al., 1994; Takata et al., 1994) . SYK has two tandem Src homology (SH) 2 domains in its amino terminal region, a linker region of 80 ± 110 amino acids, a carboxyterminal catalytic domain including sites for ATP binding and tyrosine phosphorylation and a short carboxy-terminal extension of undetermined function (Law et al., 1994; Kurosaki et al., 1995; Taniguchi et al., 1991) . Unlike the Src family of tyrosine kinases, SYK does not have a myristylation site or carboxyl-terminal negative regulatory tyrosine residues (Taniguchi et al., 1991) . Two distinct functional isoforms, SYK A and SYK B, have been reported (Latour et al., 1996 (Latour et al., , 1998 Yagi et al., 1994) . These two isoforms dier with respect to the presence (SYK A) or absence (SYK B) of a 23 amino acid peptide in their linker region. SYK A is the predominant form in human B-lineage lymphoid cells (Yagi et al., 1994) . The SH2 domains of SYK mediate intermolecular interactions by binding to phosphotyrosine-containing sequences with high anity (Chen et al., 1996; Pawson and Gish, 1992) . Recruitment of SYK to phosphorylated immunoreceptor tyrosine-based activation motifs (ITAMs) via its SH2 domains is required for B-cell antigen receptor signaling. Upon receptor activation, the tandem SH2 domains of SYK bind dual phosphotyrosine sites in the conserved ITAMs of receptor signaling chains leading to SYK activation . The SH2 domains as well as the catalytic domain of SYK are indispensable for B-cell antigen receptor-linked signal transduction . Targeted disruption of the Syk gene in the chicken B-cell line DT40 by homologous recombination knockout resulted in defective B-cell antigen receptor signaling Takata et al., 1994; Takata and Kurosaki, 1996) .
SYK also plays a pivotal role in B-lymphocyte development during early stages of B-cell ontogeny (Owen and Venkitaraman, 1996) . SYK-de®ciency impairs the in vivo dierentiation of murine pro-B cells by disrupting the signaling from the pre-B cell receptor complex (Cheng et al., 1995) and lethally irradiated mice reconstituted with SYK-de®cient fetal liver-derived lymphohematopoietic progenitor cells show a maturational block at the pro-B to pre-B cell transition stage of B-cell ontogeny (Turner et al., 1995) . In addition, SYK is required for the B-cell antigen receptor-mediated positive selection of immature B cells into the recirculating B-cell pool (Turner et al., 1997) . Although SYK has not been linked to a human disease, defective expression of the closely related T-cell tyrosine kinase ZAP-70 has been associated with severe combined immunode®ciency (Arpaia et al., 1994; Chan et al., 1994; Elder et al., 1994; Perlmutter, 1994) .
Childhood CD19 + CD10 7 pro-B cell acute lymphoblastic leukemia (ALL), including t(4;11) ALL in infants, is thought to originate from B-cell precursors with a maturational arrest at the pro-B to pre-pre-B cell stage and it is associated with a worse prognosis than CD19 + CD10 + sIgM 7 pre-pre-B/common ALL (Reaman et al., 1999; Trigg et al., 1996; Uckun et al., 1997a Uckun et al., ,b, 1998a . Since SYK-de®ciency is associated with a maturational block in murine B-cell ontogeny at the pro-B to pre-B cell transition, we examined the SYK expression pro®les of primary leukemic cells from children with pro-B cell ALL. Here we report that leukemic cells from pediatric CD19 + CD10
7 pro-B cell ALL patients have markedly reduced SYK activity. Sequencing of the RT ± PCR products of the syk mRNA in these pro-B leukemia cells revealed profoundly aberrant coding sequences with deletions or insertions. These mRNA species encode abnormal SYK proteins with a missing or truncated catalytic kinase domain. Examination of the genomic structure of the Syk gene by inter-exonic PCR and genomic cloning demonstrated that the deletions and insertions in the abnormal Syk mRNA species of pro-B leukemia cells are caused by aberrant splicing resulting in either mis-splicing, exon skipping or inclusion of alternative exons, consistent with an abnormal posttransciptional regulation of alternative splicing of Syk pre-mRNA. Our ®ndings link for the ®rst time speci®c molecular defects involving the Syk gene to a distinct category of childhood ALL. To our knowledge, this is the ®rst discovery of a speci®c tyrosine kinase de®ciency in a human hematologic malignancy.
Results and discussion
SYK tyrosine kinase activity levels of pro-B leukemia cells
We ®rst used immune complex kinase assays to compare the SYK and BTK tyrosine kinase activity levels in primary leukemic cells from 2 pro-B ALL (Pro-B #1 and Pro-B #2) and 4 pre-pre-B ALL (CON1-CON4) patients. As shown in Figure 1a , pro-B leukemia cells had substantially lower SYK activity than pre-pre-B leukemia cells, although their BTK activity levels were comparable (Figure 1b) . Notably, comparison of the 72 kDa intact SYK protein expression levels by Western blot analysis revealed less SYK protein in pro-B leukemia cells. In addition, a truncated *55 kDa SYK protein was detected in the leukemic cells from Pro-B #1 (Figure 1c ). Abundant LYN tyrosine kinase activity but no SYK activity was detected in leukemic cells from Pro-B#2) and two additional pro-B ALL patients (Pro-B#3 and Pro-B#4) (Figure 1d ). In one of these patients (Pro-B #4), LYN and SYK tyrosine kinase activity levels as well as SYK protein expression levels of the pro-B leukemia cells were compared in a repeat experiment with those of KL-2, an EBV-transformed B-lymphoblastoid cell line from a healthy volunteer donor, which was used as a positive control. As shown in Figure 1e , no SYK tyrosine kinase activity and no SYK protein were detected in leukemic cells from Pro-B#4, but their LYN tyrosine kinase activity was similar to that of KL-2 cells. Taken together, these results provided unprecedented experimental evidence for a SYK tyrosine kinase de®ciency in leukemic cells from children with pro-B ALL.
RT ± PCR analysis and molecular characterization of Syk transcripts in pro-B leukemia cells RT ± PCR using two human Syk primers was used to amplify a 1659 base pair fragment of the Syk mRNA in pro-B and pre-pre-B leukemia cells starting from the coding sequence for the second SH2 domain and extending through the entire coding region. Cloning and sequencing of the RT ± PCR products of the Syk mRNA from pro-B leukemia cells revealed profoundly aberrant coding sequences with deletions or insertions. These mRNA species encode abnormal SYK proteins with a missing or truncated catalytic kinase domain (Table 1, Figure 2) . Similar deletions or insertions were not observed in leukemic cells from two pre-pre-B ALL patients or peripheral blood mononuclear cells of three healthy volunteer donors (Table 1) .
In leukemic cells of patient Pro-B#1, a 113 bp deletion (G 1870 ± A 1982 ) in the aberrant coding sequence results in a truncating frameshift mutation starting after Arg 574 of the catalytic domain with addition of 19 novel amino acids until stop codon ( (Figures 2 and 3 ). In parallel, we used inter-exonic PCR of total human genomic DNA or cloned syk genomic DNA (P1 and lambda phage) in order to determine an overall intron-exon structure of the genomic Syk gene. From these analyses we were able to conclude that these two deletions observed in the aberrant Syk coding sequences of pro-B leukemia cells correspond to skipping of a single exon (Figure 4 ). The 113 bp deletion in Pro-B#1 corresponds to deletion of exon 12 (Figure 4a ) and the 141 bp deletion in Pro-B#3 corresponds to deletion of exon 13 ( Figure 4b ). Both deletions result from an exact skipping of a single exon with no other mutations. These studies also demonstrated that the previously reported syk B variant results from skipping of exon 7 (A 994 ± G 1062 Figure 5 ). This insertion results in a truncating frameshift after Tyr 611 near the C-terminal end of the kinase domain just upstream of an invariant In patient Pro-B#1, a frameshift mutation of SYK is predicted starting at amino acid Arg 574 with 19 amino acids until stop codon. In patient Pro-B#2, a frameshift mutation of SYK is predicted starting at Tyr 611 resulting in the insertion of a novel 23 amino acid peptide extension until stop codon. In patient Pro-B#3, an in-frame deletion of amino acids Ala 528 ± Arg 574 in SYK is predicted. In patient Pro-B#4, a frameshift mutation of SYK is predicted starting at amino acid Trp 239 with a novel 11 amino acid peptide extension until stop codon Arg 616 (with addition of 23 novel amino acids until stop codon). Using genomic PCR with primers based on the sequence of the insertion, we were able to localize this 177 bp insertion to an intronic region 771 bases downstream of exon 13 ( Figure 6 ). We designated this coding sequence exon 14 since the genomic sequence adjacent to this insertion demonstrates consensus splice donor and acceptor sites (Figure 7a ). We have observed the inclusion of this exon only in this one pro-B ALL patient and not in any of the two pre-pre-ALL patients or three healthy volunteers. The fact that the genomic region surrounding this insertion shows consensus splice sites suggests that this insertion also results from aberrant alternative splicing.
In leukemic cells from patient Pro-B#4, we detected an aberrant syk coding sequence containing a 4 bp deletion (C 865 ± G 868 ) which results in frameshift starting after Trp 239 (with 11 novel amino acids until stop codon) of the second SH2 domain eliminating the entire catalytic domain. Examination of the genomic structure surrounding this deletion suggests a possible mechanism for the generation of this abnormal transcript. This mechanism, mis-splicing of 5' end of Exon 5 is illustrated in Figure 7b .
Structural consequences of the molecular abnormalities involving the Syk coding sequence in pro-B leukemia cells
We next used a homology model of the SYK kinase domain to examine the structural basis of the functional consequences of the detected molecular abnormalities in pro-B leukemia cells (Figure 8 ). Our molecular modeling studies revealed that the aberrant SYK proteins lack some of the signi®cant secondary components of the kinase domain and are therefore not expected to be as stable or catalytically competent as the wild-type SYK: The 113 bp deletion in the SYK coding sequence of Pro-B#1 aects the N-terminal 62 amino acids, which are replaced by 19 new amino acids. The missing secondary structures include three helices (aG, aH and aI) which make up the lower section of the C-loop domain of the kinase (see yellow region in Figure 8b ). These three helices are highly conserved among protein tyrosine kinases and thus are considered important for their enzymatic function as well as structural stability. In addition, our modeling analysis indicates that a number of buried hydrophobic residues (M562, V478, I471, V475, F558, M482, F566, P541, I544, V536, A533, V634, M480, A621 and L624) are exposed as a consequence of the missing helices in this variant.
The 177 bp insertion detected in leukemic cells of Pro-B#2 aects the last 24 amino acids of the SYK kinase domain, which includes aI, distant from the active site (Figure 8c ). In addition, the hydrophobic residues including P541, A540, V555, F558, L604, M601, V475, I472, L495, M482, F558 and P598 are now exposed in this variant without conformational change. Therefore, this molecular abnormality does not have a major structural impact on the catalytic scaold and should not aect the kinase activity directly. However, several protein tyrosine kinases contain an aI We postulate that the absence of the last helix aI may compromise the structural stability of SYK. The 141 bp deletion detected in leukemic cells from Pro-B#3 results in a 47 AA deletion within the kinase domain of SYK which covers the P+1 loop region as part of the activation loop, helix aEF and helix aF (Figure 8d ). The activation loop is close to the ATP binding site and is critical for protein substrate binding. Both the aEF and the aF helices are important structural components which are shared by most kinase domains of protein tyrosine kinases. The aF helix is positioned in the center region¯anked by the aE, aI, aF, aH and aG helices. Based on our modeling analysis, the absence of the aF helix leaves a long patch of otherwise buried hydrophobic residues including A497, V478, L460, I472, V475, V622, P617 and M591 exposed to the solvent, suggesting a consequential structural rearrangement. These residues are mainly from the aE and aG helices which have extensive hydrophobic interaction with the aF helix. Therefore, this aberrant SYK protein with a missing section in the middle of C-lobe domain (see yellow region in Figure 8c ) would likely be unstable. In addition, the absence of a suitable scaold in this variant to bind a protein substrate would likely prevent catalytic activity even if the protein was stable.
The 4 bp deletion in Pro-B#4 results in a deletion including the last b strand of the Syk tantem SH2 domains as well as the kinase domain. Therefore, this truncated SYK protein would not have any kinase activity.
In summary, we examined the structure and function of SYK tyrosine kinase leukemic cells from pro-B and pre-pre-B ALL patients. Our results provide unprecedented evidence that leukemic pro-B cells have markedly reduced SYK activity. Sequencing of the reverse transcriptase-polymerase chain reaction (RT ± PCR) products of the syk mRNA in these pro-B leukemia cells revealed profoundly aberrant coding ] correspond to skipping of exons 12 and 13. (a) Normal genomic sequence surrounding exon 12 was obtained by cloning and sequencing genomic PCR products. Genomic PCR products spanning the exon 12 splice junctions were generated using two overlapping exon 12 primers (12F, 12R designated with arrows) in conjunction with primers speci®c for the upstream exon 11-11F (5'-ACTGCGTGCTGATGAAAACTAC-3') or the downstream exon 13 (13R, b). The exon 12 coding sequence is designated in upper case and intronic sequence (intron 11 (3') and intron 12 (5')) in lower case. The beginning (G 1729 ) and end (A 1869 ) of exon 12 are numbered corresponding to the syk cDNA sequence (HUMPTK, accession #L28824). The splice donor and acceptor sites are underlined. (b) Sequence of exon 13 and its surrounding intron/exon junctions. This sequence was obtained by PCR ampli®cation with exon 13 speci®c primers, primers 13F and 13R (arrows) in conjunction with primers for either the upstream exon (12F, a) or with an reverse primer speci®c for insertion (see Materials and methods). Exonic sequence is designated in upper case and intronic sequence in lower case. The beginning (G 1870 ) and end (A 1982 ) of exon 13 are shown sequences with deletions or insertions. These mRNA species encode abnormal SYK proteins with a missing or truncated catalytic kinase domain. Thus, in all four cases of pro-B ALL, the RT ± PCR analysis of Syk transcripts provided possible explanations for the biochemically documented lack of SYK tyrosine kinase activity. In contrast to pro-B leukemia cells, pre-pre-B leukemia cells and normal mature B-cells from healthy volunteers expressed wildtype Syk coding sequences. Examination of the genomic structure of the Syk gene by inter-exonic PCR and genomic cloning demonstrated that the deletions and insertions in the abnormal mRNA species of pro-B leukemia cells are caused by aberrant splicing results in either mis-splicing, exon skipping or inclusion of alternative exons, consistent with an abnormal posttranscriptional regulation of alternative splicing of Syk pre-mRNA. Although most reported mutations in leukemia involve chromosomal translocations and or point mutations, there are a few examples of exon skipping. In two patients with adult T-cell leukemia, both intact and truncated (without exon 4) Fas gene transcripts were detected (Tamiya et al., 1998) . This aberrantly spliced message was not found in normal tissue indicating that it was pathologically generated. The loss of exon 4 in the Fas gene resulted in premature termination and loss of Fas antigen expression. Aberrant IRF-1 transcripts lacking exon 2 and 3 and little or no intact IRF-1 mRNA were reported in bone marrow and PBMCs from patients with myelodysplastic syndrome (Harada et al., 1994) . The aberrant IRF-1 transcript generated an abnormal protein without a transcriptional activation domain. No mutations were found within exons or splice junctions. Similarly, we have recently reported that aberrant splicing causes the expression of truncated isoforms of the tumor suppressor protein Ikaros in leukemic cells from infants with ALL (Sun et al., 1999a,b,c) . Although the exact mechanism causing this aberrant splicing remains to be identi®ed, it was proposed to be one mechanism to inactivate tumor-suppressor genes (Harada et al., 1994) .
Our ®ndings link for the ®rst time speci®c molecular defects involving the Syk gene to an immunophenotypically distinct category of childhood ALL. To our knowledge, this is the ®rst discovery of a speci®c tyrosine kinase de®ciency in a human hematologic malignancy. The observed molecular and functional abnormalities involving SYK uniquely implicate this regulatory tyrosine kinase in leukemogenesis of childhood ALL. Further studies are necessary to further elucidate the signi®cance of SYK de®ciency in leukemogenesis. A larger series of ALL patients need to be examined to more accurately determine the true incidence of SYK de®ciency in childhood ALL and its subsets. The cause of the poor prognosis in SYK de®cient pro-B ALL has not been deciphered but implicates SYK as a regulator of the chemosensitivity of ALL cells. + common pre-pre B/pre-B leukemia who were enrolled on induction chemotherapy protocols, were used for laboratory studies. Mononuclear cell fractions containing 490% leukemic cells were isolated from the diagnostic BM aspirate samples by centrifugation on Ficoll-Hypaque density gradients, as previously described (Uckun et al., 1997b) . Informed consent for protocol enrollment was obtained from parents or legal guardians according to the Department of Health and Human Services guidelines. Peripheral blood mononuclear cells were obtained from healthy volunteer donors according to the guidelines of the Parker Hughes Institute Human Subjects Committee on the Use of Human Subjects.
Materials and methods

Cells
SYK tyrosine kinase assays and Western blot analyses
For SYK, LYN and BTK immune complex kinase assays, cells were lysed with NP-40 lysis buer (50 mM Tris, pH 8, 150 mM NaCl, 5 mM EDTA, 1% NP-40, 100 mM sodium orthovanadate, 100 mM sodium molybdate, 8 mg/ml aprotinin, 5 mg/ml leupeptin and 500 mM PMSF) and centrifuged 10 min at 13 000 g to remove insoluble material. Samples were immunoprecipitated with antisera prepared against SYK, LYN or BTK, as described (Mahajan et al., 1999; Uckun et al., 1996) . The antisera were diluted and immune complexes collected by incubation with 15 ml protein A Sepharose. After four washes with NP-40 lysis buer, the protein A Sepharose beads were washed once in kinase buer (20 mM MOPS, pH 7, 10 mM MgCl 2 ) and resuspended in the same buer. Reactions were initiated by the addition of 25 mCi[g 32 P]ATP (5000 Ci/mMole) and unlabeled ATP to a ®nal concentration of 5 mM. Reactions were terminated by boiling for 4 min in SDS sample buer. Samples were run on 9.5% SDS polyacrylamide gels and labeled proteins were detected by autoradiography.
Reverse transcriptase polymerase chain reaction (RT ± PCR) and nucleotide sequencing All RT ± PCR assays for Syk mRNA expression were performed centrally in the CCG ALL Biology Reference Laboratory, taking all due precautions to avoid false-positive results, as previously described (Sun et al., 1999a; Uckun et al., 1998b) . Brie¯y, total cellular RNA was isolated from cells using the RNeasy total RNA isolation kit (Qiagen, Santa Clarita, CA, USA). cDNA was synthesized from total RNA using random primers and Superscript II reverse transcriptase (Gibco ± BRL). Oligonucleotide primers, Syk1 (5'-TGATCCGAGCCAGAGACAACAAC-3') and Syk2 (5'-ACCCCGGGACCCAGAGAAGTG-3') were used for PCR ampli®cation of Syk mRNA. The enzyme mix Elongase (Taq polymerase plus the proof-reading (3'?5' exonuclease activity) Pyrococcus species GB-D polymerase, Gibco ± BRL) was used in a two step ampli®cation (948C, 10 s, 708C, 5 min, 35 cycles) incorporating a hot start (one cycle). RNA integrity was con®rmed by ampli®cation of the cABL mRNA, which is expressed ubiquitously in human hematopoietic cells, as previously reported (Sun et al., 1999a) . Reactions conducted with RNA from normal peripheral blood mononuclear cells were used as controls for PCR ampli®able wildtype Syk transcripts. Negative controls included PCR products from an RNA-free cDNA synthesis and ampli®cation reaction and a DNA polymerase-free reaction.
Puri®ed RT ± PCR products (QIAquickTM PCR puri®ca-tion kit, Qiagen) were cloned into the pCRII vector using the TA Cloning Kit (Invitrogen, San Diego, CA, USA). The cloned PCR products were puri®ed with a Qiagen plasmid isolation kit and sequenced automatically with the Thermo- Syk cDNA probes A 2.2 kb Syk cDNA (108 ± 2265 bp) was obtained by RT ± PCR from Jurkat cells (primer pairs, 5' ± 3'; TGGA-CACCTGCGCAGGTGTGTG, CCTGCCATCCGTCTTT-TCTCCC) and subcloned into TA cloning vector (Syk cDNA clones kindly provided by J Fargnoli and J Bolen, Bristol Myers Squibb, Princeton, NJ, USA). The insert was isolated after digestion of the construct with EcoRI followed by elution after electrophoresis on a low melt gel. This EcoRI fragment covers bases 108 ± 2265 of the Syk cDNA (HUMPTK, GenBank accession # L28824) which encompasses the entire open reading frame. This fragment was used as a probe during cloning of Syk genomic DNA. A 502 bp ScaI fragment (1095 ± 1597 bp) of this cDNA clone was also used as an internal Syk cDNA probe for the Southern blot hybridization analysis of the authenticity of the Syk RT ± PCR products. This fragment spans the 3' region of the linker domain into the 5' region of the kinase domain.
Cloning and PCR analysis of Syk genomic DNA
A lambda Fix II genomic library from Stratagene (La Jolla, CA, USA) was screened by hybridization with the full length Syk cDNA probe (Benton and Davis, 1977) . Four hybridizing phage clones were plaque-puri®ed for further analysis. Phage DNA was isolated by ultracentrifugation through a cesium chloride cushion (Yamamoto et al., 1970) . The phage DNA was PCR-ampli®ed using primers based on the Syk cDNA sequence and Primer Select Software (DNASTAR, Madison, WI, USA). P1 clones containing Syk genomic inserts were obtained from Research Genetics (Huntsville, AL, USA) after screening with the Syk cDNA probe. Ampli®cation from lambda phage or P1 DNA was performed using a mix of Taq and a proof-reading enzyme, Pwo polymerase, with either the`Expand High Fidelity System' (Boehringer-Mannheim, Indianapolis, IN, USA) or thè Expand Long Template PCR System' (Boehringer-Mannheim), according to manufacturer's recommendations.
Amplification of the genomic DNA and genomic sequence analysis of the Syk gene Genomic DNA was isolated from a normal control EBV transformed lymphocyte cell line (approximately 4610 7 cells) with the Puregene TM DNA isolation kit (Gentra Systems, Inc., Minneapolis, MN, USA) according to manufacturer's instructions. Primer pairs for genomic PCR were designed based on the Syk cDNA sequence and tested on Syk phage DNA. Ampli®ed phage DNA PCR products were cloned into plasmid PCR 2.1 with a TA cloning kit (Invitrogen, Carlsbad, CA, USA). Cy5-labeled T7 and M13 reverse primers were used to sequence the ends of the clones and thereby determine the sequence spanning the intron ± exon junctions. Primers which spanned intronic regions were subsequently employed to amplify genomic DNA with the Expand Long Template PCR System (BoehringerMann-heim). Smaller ampli®ed genomic pieces were subcloned with the TA cloning kit (Invitrogen), whereas larger genomic pieces were subcloned by electroporation into pCR-XL-TOPO with the Topo XL PCR Cloning kit (Invitrogen).
Initial sequence analysis localized the inserted region between two previously characterized exons. Two primers (one sense 5'-GGGATTCCGAGACCTCCCCTC-3' and one antisense 5'-GAGGGGAGGTCTCGGAATCCC-3') were constructed based on the insertion sequence and used for genomic PCR ampli®cation. PCR ampli®cation from control genomic DNA was performed using these primer sets in conjunction with primers for the upstream exon (5'-GGGATGAAAGGAAGTGAAGTC-3') or downstream exon (5'-GTCCCTGGGCCCGATGAGTAACA-3'). The resulting PCR products were subcloned into pCR-XL-TOPO (Invitrogen) and digested with the restriction enzyme EcoRI to determine insertion size. Clones containing inserts corresponding in size to original PCR products were sequenced for con®rmation and determination of surrounding intronic sequence.
Homology model of human SYK kinase domain
A homology model of the kinase domain of SYK was constructed using the X-ray structure of homologous insulin receptor kinase domain (IRK) (Hubbard, 1997) . The homology modeling of SYK was carried out in two steps as follows: (i) the most reasonable sequence alignment between the SYK kinase domain and a coordinate template was determined; (ii) new coordinates were assigned to the SYK kinase domain residues according to the template coordinates (based on the sequence alignment), followed by the determination of loop coordinates and an energy minimization of the entire structure.
Step 1: the Ca coordinates of the kinase domains of HCK, FGFR, IRK, and cAPK were superimposed using the InsightII program (Molecular Stimulations, Inc, San Diego, CA, USA) to provide the best overall structural comparison. All four sequences were then aligned based on the superimposition of their structures (amino acid sequences were aligned together if their Ca positions were spatially related to each other). The sequence alignment accommodated such features as loops in a protein which diered from the other protein sequences. The structural superimposition was done using the Homology module of the InsightII program and a Silicon Graphics INDIGO2 computer (Silicon Graphics, Mountain View, CA, USA). The sequence alignment was manually adjusted based on the previously mentioned considerations, and produced a sequence variation pro®le for each superimposed Ca position. The sequence variation pro®le served as a basis for the next procedure, sequence alignment of all four proteins with SYK kinase domain. In this procedure, the sequence of SYK kinase domain was read into the program and manually aligned with the four known kinase proteins based on the sequence variation pro®le described previously.
Step 2: a set of 3D coordinates was assigned to the SYK kinase domain sequence using the 3D coordinates of IRK as a template, using the Homology module within the InsightII program. (Molecular Stimulations Inc, San Diego, CA, USA). The coordinates for a loop region where a sequence insertion occurs was chosen from a limited number of possibilities automatically generated by the program and manually adjusted to a more ideal geometry using the program CHAIN (Sack, 1988) . Finally, the constructed model of SYK kinase domain was subjected to energy minimization using the X-plor program (Brunger, 1992) so that any steric strain introduced during the model-building process could be relieved. The model was screened for unfavorable steric contacts and if necessary such side chains were remodeled either by using a rotamer library database or by manually rotating the respective side chains. Aberrant SYK proteins were illustrated by labeling the sequences which are dierent from the wild-type SYK with yellow color using GRASP. The structural changes in SYK variants were analysed in CHAIN. The homology model of SYK kinase domain has the expected protein kinase fold with the catalytic site in the center dividing the kinase domain into two lobes. It is composed of a smaller N-terminal lobe connected by ā exible hinge to a larger C-terminal lobe. The N-terminal lobe is rich in b-strands, whereas the C-terminal region is mostly helical. The catalytic site is de®ned by two b-sheets that form an interface at the cleft between the two lobes.
